Cross‐talk between pro‐inflammatory transcription factors and glucocorticoids

Asthma is a chronic inflammatory disease of the airway that is characterized by cellular infiltration and activation. These processes are induced by overexpression of chemokines and cytokines, such as eotaxin, IL‐1β and GM‐CSF. These mediators are downstream targets for the transcription factors activator protein‐1 (AP‐1) and nuclear factor‐κB (NF‐κB), which control the expression of most immunomodulatory genes and whose activity and expression are elevated in asthma. Glucocorticoids are the most effective anti‐inflammatory drugs used in the treatment of chronic inflammatory diseases such as asthma. They act by binding to a specific glucocorticoid receptor (GR) that on activation translocates to the nucleus and either increases (transactivates) or decreases (transrepresses) the expression of responsive genes. Transrepression is the major mechanism of glucocorticoid action in inhibiting inflammatory gene expression. Thus, the ability of the transciption factors AP‐1 and NF‐κB to induce gene transcription is attenuated by GR. Although only 5–10% of asthmatic subjects are glucocorticoid‐insensitive, these subjects account for over 50% of the health‐care costs for asthma (> $6 billion per annum). Examining these patients also gives an insight into important aspects of glucocorticoid action in controlling inflammation and into the development of potential new drugs. Biochemical and genomic studies have indicated abnormal induction of the c‐Jun N‐terminal kinase (JNK) pathway in some of these patients. The ability of most patients to respond to dexamethasone with induction of histone acetylation correlated with nuclear translocation of GR. However, a subgroup of these patients had an inability to correctly interact with the basal transcription complex in spite of high levels of nuclear GR. This suggests that cross‐talk between pro‐ and anti‐inflammatory transcription factors may modulate activation of the transcriptional complex and thereby reduce steroid actions.

[1]  I. Adcock,et al.  Molecular mechanisms of glucocorticosteroid actions. , 2000, Pulmonary pharmacology & therapeutics.

[2]  C. Calkhoven,et al.  Multiple steps in the regulation of transcription-factor level and activity. , 1996, The Biochemical journal.

[3]  W. Fiers,et al.  TRAF2 plays a dual role in NF‐κB‐dependent gene activation by mediating the TNF‐induced activation of p38 MAPK and IκB kinase pathways , 1998 .

[4]  G. Haegeman,et al.  p38 and Extracellular Signal-regulated Kinase Mitogen-activated Protein Kinase Pathways Are Required for Nuclear Factor-κB p65 Transactivation Mediated by Tumor Necrosis Factor* , 1998, The Journal of Biological Chemistry.

[5]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[6]  N. Katunuma,et al.  Inhibition by 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, an inhibitor of protein kinase C, of enzyme induction by glucocorticoid and of nuclear translocation of glucocorticoid-receptor complexes. , 1987, Biochemical and biophysical research communications.

[7]  M. Karin The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[8]  A. Muñoz,et al.  Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. , 1997, Genes & development.

[9]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[10]  K. Kaestner,et al.  DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival , 1998, Cell.

[11]  G. Chrousos,et al.  Mechanisms of Glucocorticoid‐Resistant Asthma a , 1998, Annals of the New York Academy of Sciences.

[12]  W. Fiers,et al.  TRAF2 plays a dual role in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IkappaB kinase pathways. , 1998, FEBS letters.

[13]  T. Troost,et al.  Glucocorticoids decrease c-fosexpression in human nasal polyps in vivo , 1998, Thorax.

[14]  W. Greene,et al.  Cross‐coupling of the NF‐kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. , 1993, The EMBO journal.

[15]  W. V. Berghe,et al.  Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. , 2000, Biochemical pharmacology.

[16]  N. Barden,et al.  Decreased glucocorticoid receptor activity following glucocorticoid receptor antisense RNA gene fragment transfection , 1991, Molecular and cellular biology.

[17]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[18]  A. Wolffe,et al.  Transcription: Gene control by targeted histone acetylation , 1998, Current Biology.

[19]  E. Zandi,et al.  IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. , 1998, Nature.

[20]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[21]  J. Bousquet,et al.  c-fos proto-oncogene expression in bronchial biopsies of asthmatics. , 1992, American journal of respiratory cell and molecular biology.

[22]  K. Chung,et al.  Expression of RANTES mRNA and protein in airways of patients with mild asthma. , 1996, American journal of respiratory and critical care medicine.

[23]  A. Sousa,et al.  In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. , 1999, The Journal of allergy and clinical immunology.

[24]  T. Lee,et al.  Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. , 1996, American journal of respiratory and critical care medicine.

[25]  J. Eder,et al.  Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? , 1997, Trends in pharmacological sciences.

[26]  M. Karin,et al.  Mitogen-activated protein kinase cascades and regulation of gene expression. , 1996, Current opinion in immunology.

[27]  P. Jeffery,et al.  Structural and inflammatory changes in COPD: a comparison with asthma. , 1998, Thorax.

[28]  I. Adcock,et al.  Steroid resistance in asthma. , 1995, QJM : monthly journal of the Association of Physicians.

[29]  T. Maniatis,et al.  MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Mackman,et al.  Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. , 1997, Journal of immunology.

[31]  I. Adcock,et al.  Glucocorticoid receptor localization in normal and asthmatic lung. , 1996, American journal of respiratory and critical care medicine.

[32]  T. Meyer,et al.  A Weak TATA Box Is a Prerequisite for Glucocorticoid-dependent Repression of the Osteocalcin Gene* , 1997, The Journal of Biological Chemistry.

[33]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[34]  M. Lindsay,et al.  IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. , 1998, The Journal of biological chemistry.

[35]  I. Adcock,et al.  Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. , 1998, American journal of respiratory and critical care medicine.

[36]  M. Lindsay,et al.  Pharmacology of the eosinophil. , 1999, Pharmacological reviews.

[37]  G. Nabel,et al.  Regulation of NF-κB by Cyclin-Dependent Kinases Associated with the p300 Coactivator , 1997, Science.

[38]  J. Bousquet,et al.  Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. , 1992, The American review of respiratory disease.

[39]  I. Adcock,et al.  Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. , 1998, The Journal of clinical investigation.

[40]  M. Lindsay,et al.  IκBα Degradation and Nuclear Factor-κB DNA Binding Are Insufficient for Interleukin-1β and Tumor Necrosis Factor-α-induced κB-dependent Transcription* , 1998, The Journal of Biological Chemistry.

[41]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[42]  A. Manning Transcription factors: a new frontier for drug discovery , 1996 .

[43]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[44]  J. Bousquet,et al.  Glucocorticoid receptors in bronchial epithelial cells in asthma. , 1998, American journal of respiratory and critical care medicine.

[45]  I. Adcock,et al.  Steroid Resistance in Asthma: Molecular Mechanisms , 1996 .

[46]  M. Karin New Twists in Gene Regulation by Glucocorticoid Receptor: Is DNA Binding Dispensable? , 1998, Cell.

[47]  K. Yamamoto,et al.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. , 2000, Genes & development.

[48]  I. Adcock,et al.  Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma , 1995, The Journal of experimental medicine.

[49]  J. Yasuda,et al.  A mammalian scaffold complex that selectively mediates MAP kinase activation. , 1998, Science.

[50]  S. Logan,et al.  Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  K. Chung,et al.  Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.

[52]  K. Chung,et al.  Neutrophilic inflammation in severe persistent asthma. , 1999, American journal of respiratory and critical care medicine.

[53]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[54]  W. Fiers,et al.  The p38/RK mitogen‐activated protein kinase pathway regulates interleukin‐6 synthesis response to tumor necrosis factor. , 1996, The EMBO journal.